ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for ASTELLAS PHARMA US, INC.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 21, 2019 | $50,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Jan 22, 2020 | $50,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to Medicare Part D, including non-interference, rebate policy issues Issues related to drug pricing, value, and transparency, generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Budget/Appropriations BUD
House and Senate Appropriations for FY ending Sept. 30, 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Law Enforcement/Crime/Criminal Justice LAW
Issues related to lobbying disclosure for US affiliates
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Health Issues HCR
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Issues related to drug pricing and value, generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.